Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102218 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Phase 2 study, sponsored by Fresenius Medical Care North America.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01102218: Clinical Trial Phase 2 study, sponsored by Fresenius Medical Care North America.
NCT01102218 is a Phase 2 study that was terminated before completion, run by Fresenius Medical Care North America. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01102218, a Phase 2 study, was terminated before completion, sponsored by Fresenius Medical Care North America.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease. Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown promise in improving the treatment of patients with anemia. This study will examine the use of pentoxifylline for the treatment of anemia in chronic kidney disease.
Primary Outcome
Erythropoietin dose is amount needed to maintain a hemoglobin between 11 and 12 mg/dL.
Interventions
- DRUG Pentoxifylline
- DRUG Erythropoietin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Why NCT01102218 stopped before completion
NCT01102218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Pentoxifylline is the first listed.
NCT01102218 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01102218 about?
NCT01102218 is a clinical study titled "A Safety Study of Pentoxifylline for the Treatment of Anemia". Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease. Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown promise in improving the treatment of patient...
What is the current status of trial NCT01102218?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2010-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01102218?
The interventions under investigation include: Pentoxifylline (DRUG), Erythropoietin (DRUG).
Who is sponsoring clinical trial NCT01102218?
This trial is sponsored by Fresenius Medical Care North America, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01102218's enrollment target sits among peer trials
48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia